Related Experiment Videos
Matrix metalloproteinase-9 (MMP-9) expression in childhood osseous osteosarcoma
B P Himelstein1, N Asada, M R Carlton
1Department of Pediatrics, Children's Hospital of Philadelphia, PA 19104, USA. Himelstein@kermit.oncol.chop.edu
Medical and Pediatric Oncology
|December 4, 1998
Summary
Matrix metalloproteinase-9 (MMP-9) is highly expressed in osteosarcoma tumors and metastases. This suggests MMP-9 may play a role in the metastatic behavior of this pediatric bone cancer.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Osteosarcoma frequently metastasizes to the lungs, with over 80% of patients developing pulmonary metastases after surgical treatment.
- Current methods lack reliable predictors for micrometastasis in osteosarcoma patients.
- Matrix metalloproteinases (MMPs), particularly MMP-9 (gelatinase B), are implicated in tumor invasion and metastasis due to their matrix-degrading properties.
Purpose of the Study:
- To investigate the association between matrix metalloproteinase-9 (MMP-9) expression and the metastatic behavior of osteosarcoma.
- To determine if MMP-9 expression is a common feature in primary and metastatic osteosarcoma lesions.
Main Methods:
- Immunohistochemical analysis of pediatric primary osseous osteosarcomas and metastatic lesions.
- Utilized a monoclonal antibody to detect and quantify MMP-9 expression in tumor samples.
Main Results:
- Intense MMP-9 immunostaining was observed in the majority of tumor cells across all pretreatment osteosarcoma samples.
- Post-chemotherapy samples showed similar MMP-9 staining patterns, though with a reduced number of positive cells.
- Four out of five examined metastatic lesions exhibited intense MMP-9 immunostaining.
Conclusions:
- MMP-9 expression is prevalent in both primary and metastatic osteosarcoma.
- These findings support the need for further investigation into the specific role of MMP-9 in the pathogenesis and progression of pediatric osteosarcoma.